Gyre Therapeutics, Inc. (GYRE) — Stock Score Summary

Gyre Therapeutics, Inc. (GYRE) has a MoatMap StockRank of 44/100 based on Quality (66/100), Value (21/100), and Momentum (44/100) factor scores. The current signal is HOLD. Gyre Therapeutics is a clinical-stage biotech focused on organ fibrosis. While it has a high quantitative quality score, it is pre-revenue and highly speculative, failing our requirement for predictable owner earnings and established moats.

Gyre Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapeutics for fibrotic diseases. It leverages its proprietary platform to target key pathways involved in fibrosis, aiming to address significant unmet medical needs in conditions like idiopathic pulmonary fibrosis (IPF). Its specialized focus on complex fibrotic diseases positions it in a high-potential therapeutic area.

Key Financial Metrics

Price$6.16
Market Cap$557M
P/E (Forward)103.17
Price/Book5.58
Return on Equity-3.1%
Return on Invested Capital7.8%
Debt/Equity0.60
Gross Margin95.1%
Operating Margin-30.2%
Revenue Growth2.1%
Free Cash Flow$10M

Gyre Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Gyre Therapeutics, Inc.’s (GYRE) StockRank?
MoatMap’s StockRank for Gyre Therapeutics, Inc. (GYRE) is 44/100, with a Hold signal. It is a composite of Quality (66), Value (21), and Momentum (44) factor ranks across MoatMap’s 19,000+ stock universe.
Does Gyre Therapeutics, Inc. have an economic moat?
Gyre Therapeutics, Inc. (GYRE) has a Quality factor score of 66/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Gyre Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Gyre Therapeutics, Inc. (GYRE) is Hold, based on a StockRank of 44/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Gyre Therapeutics, Inc. in?
Gyre Therapeutics, Inc. (GYRE) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksGYRE deep dive reportAI ChampionsHow we score stocksSense-check another stock